Recombinant multi-species KAT6B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis

Genemedi produces recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine KAT6B protein for cell curture, in vitro study, in vivo study, benchmark, drug discovery & MOA research and positive control for the diagnosis.
The protein encoded by this gene is a histone acetyltransferase and component of the MOZ/MORF protein complex. In addition to its acetyltransferase activity, the encoded protein has transcriptional activation activity in its N-terminal end and transcriptional repression activity in its C-terminal end. This protein is necessary for RUNX2-dependent transcriptional activation and could be involved in brain development. Mutations have been found in patients with genitopatellar syndrome. A translocation of this gene and the CREBBP gene results in acute myeloid leukemias. Three transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Mar 2012]
The Alternative Names of target: B130044K16Rik,GTPTS,Histone acetyltransferase KAT6B,Histone acetyltransferase MOZ2,KAT6B,Kat6b,MORF,MOZ,MOZ2,MYST-4,MYST4,Monocytic leukemia zinc finger protein-related factor,Morf,Myst4,RGD1566399,SAS2 and TIP60 protein 4 (MYST-4),YBF2/SAS3,ZC2HC6B,mKIAA0383,qkf,querkopf

Target products collectionGo to KAT6B products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No. Product Name Species Reactivity
GM-Tg-hg-T98275-Ag-1/ GM-Tg-hg-T98275-Ag-2 Human KAT6B protein Human
GM-Tg-rg-T98275-Ag-1/ GM-Tg-rg-T98275-Ag-2 Rat KAT6B protein Rat
GM-Tg-mg-T98275-Ag-1/ GM-Tg-mg-T98275-Ag-2 Mouse KAT6B protein Mouse
GM-Tg-cynog-T98275-Ag-1/ GM-Tg-cynog-T98275-Ag-2 Cynomolgus/Rhesus macaque KAT6B protein Cynomolgus/ Rhesus macaque
GM-Tg-felg-T98275-Ag-1/ GM-Tg-felg-T98275-Ag-2 Feline KAT6B protein Feline
GM-Tg-cang-T98275-Ag-1/ GM-Tg-cang-T98275-Ag-2 Canine KAT6B protein Canine
GM-Tg-bovg-T98275-Ag-1/ GM-Tg-bovg-T98275-Ag-2 Bovine KAT6B protein Bovine
GM-Tg-equg-T98275-Ag-1/ GM-Tg-equg-T98275-Ag-2 Equine KAT6B protein Equine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No. GM-Tg-hg-T98275-Ag-1/ GM-Tg-hg-T98275-Ag-2; GM-Tg-rg-T98275-Ag-1/ GM-Tg-rg-T98275-Ag-2;
GM-Tg-mg-T98275-Ag-1/ GM-Tg-mg-T98275-Ag-2; GM-Tg-cynog-T98275-Ag-1/ GM-Tg-cynog-T98275-Ag-2;
GM-Tg-felg-T98275-Ag-1/ GM-Tg-felg-T98275-Ag-2; GM-Tg-cang-T98275-Ag-1/ GM-Tg-cang-T98275-Ag-2;
GM-Tg-bovg-T98275-Ag-1/ GM-Tg-bovg-T98275-Ag-2; GM-Tg-equg-T98275-Ag-1/ GM-Tg-equg-T98275-Ag-2
Products Name KAT6B protein
Species Human, Cynomolgus/ Rhesus macaque, rat, mouse, Feline, Canine, Bovine, Equine
Target Name KAT6B
Protein Sub-location Introcelluar Protein
Isotypes Recombinant protein
Expression platform Mammalian cell
Bioactivity validation Affintiy&bioactivity validated by ELISA, cell culture validated.
Tag His
Products description Recombinant Human, Cynomolgus/ Rhesus macaque, Rat, Mouse, Feline, Canine, Bovine, Equine KAT6B protein was expressed in mammalian cell expression system and is expressed with 6 HIS tag at the C-terminus for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Purity Purity: ≥95% (SDS-PAGE)
Application In vitro study, in vivo study, benchmark, positive control for the diagnosis. Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference






    About Gmab

    GDU
    GDU

    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.